Repligen (RGEN) Competitors $124.79 +5.14 (+4.30%) Closing price 04:00 PM EasternExtended Trading$121.55 -3.24 (-2.60%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, INCY, UTHR, NBIX, BMRN, and EXELShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation. Do analysts rate RGEN or TECH? Repligen presently has a consensus price target of $169.45, indicating a potential upside of 35.79%. Bio-Techne has a consensus price target of $69.42, indicating a potential upside of 21.59%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Bio-Techne 0 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.69 Which has more risk & volatility, RGEN or TECH? Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Which has preferable earnings and valuation, RGEN or TECH? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$634.44M11.07-$25.51M-$0.25-499.16Bio-Techne$1.22B7.34$73.40M$0.46124.11 Is RGEN or TECH more profitable? Bio-Techne has a net margin of 6.02% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.43% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-2.05% 4.61% 3.24% Bio-Techne 6.02%13.43%10.32% Does the media favor RGEN or TECH? In the previous week, Repligen had 6 more articles in the media than Bio-Techne. MarketBeat recorded 16 mentions for Repligen and 10 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.45 beat Repligen's score of 1.32 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 12 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in RGEN or TECH? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 3.9% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryBio-Techne beats Repligen on 12 of the 17 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.02B$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-499.1421.1431.1525.96Price / Sales11.07398.37475.15122.97Price / Cash39.1343.0937.1558.38Price / Book3.408.079.116.39Net Income-$25.51M-$54.72M$3.26B$265.56M7 Day Performance0.35%2.62%2.11%1.98%1 Month Performance9.35%7.63%5.12%1.33%1 Year Performance-15.73%13.11%31.25%21.15% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.8648 of 5 stars$124.79+4.3%$169.45+35.8%-21.8%$7.02B$634.44M-499.141,778News CoveragePositive NewsTECHBio-Techne4.8241 of 5 stars$50.15-0.5%$69.42+38.4%-25.7%$7.86B$1.22B109.023,100Positive NewsDividend AnnouncementAnalyst UpgradeAAgilent Technologies4.8849 of 5 stars$114.22-0.3%$139.77+22.4%-16.3%$32.45B$6.51B28.2017,900News CoveragePositive NewsUpcoming EarningsDHRDanaher4.7347 of 5 stars$199.83-0.4%$247.61+23.9%-24.7%$143.09B$23.88B42.5263,000Positive NewsTMOThermo Fisher Scientific4.9385 of 5 stars$462.59+0.4%$593.00+28.2%-20.8%$174.68B$43.21B26.75125,000Trending NewsInsider TradeAnalyst RevisionBIIBBiogen4.8527 of 5 stars$128.00-2.0%$185.63+45.0%-32.5%$18.77B$9.68B12.247,605Positive NewsINCYIncyte4.7354 of 5 stars$79.19+1.0%$81.20+2.5%+34.9%$15.46B$4.24B18.002,617Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9113 of 5 stars$300.43-0.4%$379.69+26.4%-11.6%$13.55B$2.88B11.731,305Positive NewsInsider TradeNBIXNeurocrine Biosciences4.8699 of 5 stars$123.98-0.8%$160.90+29.8%-10.3%$12.30B$2.51B36.681,800Positive NewsBMRNBioMarin Pharmaceutical4.9979 of 5 stars$56.80-0.9%$93.17+64.0%-37.3%$10.91B$2.85B16.853,040EXELExelixis4.9113 of 5 stars$37.41-0.8%$44.44+18.8%+47.0%$10.07B$2.17B17.991,147Trending NewsAnalyst Revision Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access